Concepedia

Wendy B. Young

WB

Statistics

Publications

15

Citations

1.2K

H-Index

15

Active since

2001

Affiliations

Gilead Sciences (United States)(Current)

Wendy B. Young is an author at Gilead Sciences (United States) specializing in pharmacology, medicinal chemistry, and tyrosine kinase inhibitors.

Publications per year

2001–2020

15

Publications

15

Specific Btk inhibition suppresses B cell– and myeloid cell–mediated arthritis

Julie A. Di Paolo, Tao Huang, Mercedesz Balázs et al. · Nature Chemical Biology · 2010 · 332 citations · Full text

, , +16

Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development

James J. Crawford, Adam R. Johnson, Dinah Misner et al. · Journal of Medicinal Chemistry · 2018 · 247 citations · Full text

, , +17

Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations

Adam R. Johnson, Pawan Bir Kohli, Arna Katewa et al. · ACS Chemical Biology · 2016 · 134 citations · Full text

, , +17

Human T Cells Armed with Her2/neu Bispecific Antibodies Divide, Are Cytotoxic, and Secrete Cytokines with Repeated Stimulation

Ryan C. Grabert, Leslie P. Cousens, Janelle A. Smith et al. · Clinical Cancer Research · 2006 · 79 citations · Full text

, , +17

Pyrazolopyridine Inhibitors of B-Raf<sup>V600E</sup>. Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors

Steve Wenglowsky, Li Ren, Kateri A. Ahrendt et al. · ACS Medicinal Chemistry Letters · 2011 · 66 citations · Full text

, , +15

1–5 of 15